Nicox verifies patent extension eligibility at USPTO

In a boon for eye care specialist Nicox, the United States Patent and Trademark Office (USPTO) has confirmed that one of its three patents covering a glaucoma treatment could be extended by up to five years.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Medtech

It’s time to review patent eligibility for diagnostic methods

27 June 2023 More clarity is needed on the application of Alice and Mayo to patent eligibility—particularly for firms developing innovative medical diagnostic techniques, say Kara Specht and Yinan Liu of Finnegan.

Americas

Pressure-reducing eye drop patents in dispute

5 July 2022 Licensing partners aim to prevent the introduction of a proposed eye drop generic treatment before the expiration of four patents.

article

USPTO told to avoid negative focus on patent thickets

28 February 2023 Pharma trade body highlighted negative narratives involving continuation patents | Such IP “essential for ongoing research and development” | USPTO requested comments following criticism of patent thickets.